Research programme - Antibiotics - QBiotics
Latest Information Update: 14 Apr 2023
At a glance
- Originator QBiotics
- Class Antibacterials; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Bacterial infections
Most Recent Events
- 08 Apr 2023 Research programme - Antibiotics - QBiotics is available for licensing as of 14 Apr 2023. https://qbiotics.com/(Qbiotics pipeline, April 2023)
- 08 Apr 2023 Qbiotics has patents pending for research programme in major jurisdictions (Qbiotics pipeline, April 2023)
- 08 Apr 2023 Early research in Bacterial infections in Australia (unspecified route), prior to April 2023 (Qbiotics pipeline, April 2023)